메뉴 건너뛰기




Volumn 49, Issue 4, 2012, Pages 304-311

Immunomodulatory Treatment of Myelodysplastic Syndromes: Antithymocyte Globulin, Cyclosporine, and Alemtuzumab

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CORTICOSTEROID; CYCLOSPORIN; ETANERCEPT; RAPAMYCIN; THYMOCYTE ANTIBODY;

EID: 84867603436     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2012.07.004     Document Type: Article
Times cited : (35)

References (48)
  • 1
    • 0018117957 scopus 로고
    • Treatment of severe aplastic anemia with antilymphocyte globulin and androgens
    • Gluckman E., Devergie A., Faille A., et al. Treatment of severe aplastic anemia with antilymphocyte globulin and androgens. Exp Hematol 1978, 6:679-687.
    • (1978) Exp Hematol , vol.6 , pp. 679-687
    • Gluckman, E.1    Devergie, A.2    Faille, A.3
  • 2
    • 0033973769 scopus 로고    scopus 로고
    • Myelodysplastic syndrome and aplastic anemia: distinct entities or diseases linked by a common pathophysiology?
    • Barrett J., Saunthararajah Y., Molldrem J. Myelodysplastic syndrome and aplastic anemia: distinct entities or diseases linked by a common pathophysiology?. Semin Hematol 2000, 37:15-29.
    • (2000) Semin Hematol , vol.37 , pp. 15-29
    • Barrett, J.1    Saunthararajah, Y.2    Molldrem, J.3
  • 3
    • 41849113445 scopus 로고    scopus 로고
    • Autoimmune mechanisms in the pathophysiology of myelodysplastic syndromes and their clinical relevance
    • Barrett A.J., Sloand E. Autoimmune mechanisms in the pathophysiology of myelodysplastic syndromes and their clinical relevance. Curr Hematol Malig Rep 2008, 3:23-28.
    • (2008) Curr Hematol Malig Rep , vol.3 , pp. 23-28
    • Barrett, A.J.1    Sloand, E.2
  • 4
    • 79951980136 scopus 로고    scopus 로고
    • Targeting immune dysregulation in myelodysplastic syndromes
    • Olnes M.J., Sloand E.M. Targeting immune dysregulation in myelodysplastic syndromes. JAMA 2011, 305:814-819.
    • (2011) JAMA , vol.305 , pp. 814-819
    • Olnes, M.J.1    Sloand, E.M.2
  • 7
    • 0035136385 scopus 로고    scopus 로고
    • Coincident myelodysplastic syndrome and T-cell large granular lymphocytic disease: clinical and pathophysiological features
    • Saunthararajah Y., Molldrem J.L., Rivera M., et al. Coincident myelodysplastic syndrome and T-cell large granular lymphocytic disease: clinical and pathophysiological features. Br J Haematol 2001, 112:195-200.
    • (2001) Br J Haematol , vol.112 , pp. 195-200
    • Saunthararajah, Y.1    Molldrem, J.L.2    Rivera, M.3
  • 8
    • 79955444925 scopus 로고    scopus 로고
    • Immune alterations in untreated and treated myelodysplastic syndrome
    • Mewawalla P., Dasanu C.A. Immune alterations in untreated and treated myelodysplastic syndrome. Expert Opin Drug Saf 2011, 10:351-361.
    • (2011) Expert Opin Drug Saf , vol.10 , pp. 351-361
    • Mewawalla, P.1    Dasanu, C.A.2
  • 9
    • 61849168098 scopus 로고    scopus 로고
    • IL-17-producing CD4(+) T cells, pro-inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome
    • Kordasti S.Y., Afzali B., Lim Z., et al. IL-17-producing CD4(+) T cells, pro-inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome. Br J Haematol 2009, 145:64-72.
    • (2009) Br J Haematol , vol.145 , pp. 64-72
    • Kordasti, S.Y.1    Afzali, B.2    Lim, Z.3
  • 11
    • 0036400123 scopus 로고    scopus 로고
    • Molecular and flow cytometric characterization of the CD4 and CD8 T-cell repertoire in patients with myelodysplastic syndrome
    • Melenhorst J.J., Eniafe R., Follmann D., Nakamura R., Kirby M., Barrett A.J. Molecular and flow cytometric characterization of the CD4 and CD8 T-cell repertoire in patients with myelodysplastic syndrome. Br J Haematol 2002, 119:97-105.
    • (2002) Br J Haematol , vol.119 , pp. 97-105
    • Melenhorst, J.J.1    Eniafe, R.2    Follmann, D.3    Nakamura, R.4    Kirby, M.5    Barrett, A.J.6
  • 12
    • 76749142133 scopus 로고    scopus 로고
    • Abnormalities of the alphabeta T-cell receptor repertoire in advanced myelodysplastic syndrome
    • Campregher P.V., Srivastava S.K., Deeg H.J., Robins H.S., Warren E.H. Abnormalities of the alphabeta T-cell receptor repertoire in advanced myelodysplastic syndrome. Exp Hematol 2010, 38:202-212.
    • (2010) Exp Hematol , vol.38 , pp. 202-212
    • Campregher, P.V.1    Srivastava, S.K.2    Deeg, H.J.3    Robins, H.S.4    Warren, E.H.5
  • 13
    • 67650065350 scopus 로고    scopus 로고
    • Patients with myelodysplastic syndromes display several T-cell expansions, which are mostly polyclonal in the CD4(+) subset and oligoclonal in the CD8(+) subset
    • Fozza C., Contini S., Galleu A., et al. Patients with myelodysplastic syndromes display several T-cell expansions, which are mostly polyclonal in the CD4(+) subset and oligoclonal in the CD8(+) subset. Exp Hematol 2009, 37:947-955.
    • (2009) Exp Hematol , vol.37 , pp. 947-955
    • Fozza, C.1    Contini, S.2    Galleu, A.3
  • 14
    • 34547957665 scopus 로고    scopus 로고
    • CD4+CD25 high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS)
    • Kordasti S.Y., Ingram W., Hayden J., et al. CD4+CD25 high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS). Blood 2007, 110:847-850.
    • (2007) Blood , vol.110 , pp. 847-850
    • Kordasti, S.Y.1    Ingram, W.2    Hayden, J.3
  • 15
    • 84859584423 scopus 로고    scopus 로고
    • Are T-cell dysfunctions the other side of the moon in the pathogenesis of myelodysplastic syndromes?
    • Fozza C., Longinotti M. Are T-cell dysfunctions the other side of the moon in the pathogenesis of myelodysplastic syndromes?. Eur J Haematol 2012, 88:380-387.
    • (2012) Eur J Haematol , vol.88 , pp. 380-387
    • Fozza, C.1    Longinotti, M.2
  • 16
    • 7344223859 scopus 로고    scopus 로고
    • Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vbeta profiles
    • Molldrem J.J., Jiang Y.Z., Stetler-Stevenson M., Mavroudis D., Hensel N., Barrett A.J. Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vbeta profiles. Br J Haematol 1998, 102:1314-1322.
    • (1998) Br J Haematol , vol.102 , pp. 1314-1322
    • Molldrem, J.J.1    Jiang, Y.Z.2    Stetler-Stevenson, M.3    Mavroudis, D.4    Hensel, N.5    Barrett, A.J.6
  • 17
    • 0037111548 scopus 로고    scopus 로고
    • Loss of T-lymphocyte clonal dominance in patients with myelodysplastic syndrome responsive to immunosuppression
    • Kochenderfer J.N., Kobayashi S., Wieder E.D., Su C., Molldrem J.J. Loss of T-lymphocyte clonal dominance in patients with myelodysplastic syndrome responsive to immunosuppression. Blood 2002, 100:3639-3645.
    • (2002) Blood , vol.100 , pp. 3639-3645
    • Kochenderfer, J.N.1    Kobayashi, S.2    Wieder, E.D.3    Su, C.4    Molldrem, J.J.5
  • 18
    • 23044473715 scopus 로고    scopus 로고
    • Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome
    • Sloand E.M., Mainwaring L., Fuhrer M., et al. Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome. Blood 2005, 106:841-851.
    • (2005) Blood , vol.106 , pp. 841-851
    • Sloand, E.M.1    Mainwaring, L.2    Fuhrer, M.3
  • 19
    • 79953100658 scopus 로고    scopus 로고
    • T-cell immune responses to Wilms tumor 1 protein in myelodysplasia responsive to immunosuppressive therapy
    • Sloand E.M., Melenhorst J.J., Tucker Z.C., et al. T-cell immune responses to Wilms tumor 1 protein in myelodysplasia responsive to immunosuppressive therapy. Blood 2011, 117:2691-2699.
    • (2011) Blood , vol.117 , pp. 2691-2699
    • Sloand, E.M.1    Melenhorst, J.J.2    Tucker, Z.C.3
  • 20
    • 0031888417 scopus 로고    scopus 로고
    • Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow
    • Jonasova A., Neuwirtova R., Cermak J., et al. Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. Br J Haematol 1998, 200:304-309.
    • (1998) Br J Haematol , vol.200 , pp. 304-309
    • Jonasova, A.1    Neuwirtova, R.2    Cermak, J.3
  • 21
    • 77952602288 scopus 로고    scopus 로고
    • Anti-thymocyte globulin plus etanercept as therapy for myelodysplastic syndromes (MDS): a phase II study
    • Scott B.L., Ramakrishnan A., Fosdal M., et al. Anti-thymocyte globulin plus etanercept as therapy for myelodysplastic syndromes (MDS): a phase II study. Scott Br J Haematol 2010, 149:706-710.
    • (2010) Scott Br J Haematol , vol.149 , pp. 706-710
    • Scott, B.L.1    Ramakrishnan, A.2    Fosdal, M.3
  • 23
    • 23044473715 scopus 로고    scopus 로고
    • Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome
    • Sloand E.M., Mainwaring L., Fuhrer M., et al. Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome. Blood 2005, 106:841-851.
    • (2005) Blood , vol.106 , pp. 841-851
    • Sloand, E.M.1    Mainwaring, L.2    Fuhrer, M.3
  • 24
    • 45149093744 scopus 로고    scopus 로고
    • Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy
    • Sloand E.M., Wu C.O., Greenberg P., Young N., Barrett J. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J Clin Oncol 2008, 26:2505-2511.
    • (2008) J Clin Oncol , vol.26 , pp. 2505-2511
    • Sloand, E.M.1    Wu, C.O.2    Greenberg, P.3    Young, N.4    Barrett, J.5
  • 25
    • 0036720903 scopus 로고    scopus 로고
    • HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome
    • Saunthararajah Y., Nakamura R., Nam J.M., et al. HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood 2002, 100:1570-1574.
    • (2002) Blood , vol.100 , pp. 1570-1574
    • Saunthararajah, Y.1    Nakamura, R.2    Nam, J.M.3
  • 26
    • 0141923848 scopus 로고    scopus 로고
    • A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome
    • Saunthararajah Y., Nakamura R., Wesley R., Wang Q.J., Barrett A.J. A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome. Blood 2003, 102:3025-3027.
    • (2003) Blood , vol.102 , pp. 3025-3027
    • Saunthararajah, Y.1    Nakamura, R.2    Wesley, R.3    Wang, Q.J.4    Barrett, A.J.5
  • 27
    • 33846692197 scopus 로고    scopus 로고
    • Treatment of myelodysplastic syndrome with cyclosporin A
    • Chen S., Jiang B., Da W., Gong M., Guan M. Treatment of myelodysplastic syndrome with cyclosporin A. Int J Hematol 2007, 85:11-17.
    • (2007) Int J Hematol , vol.85 , pp. 11-17
    • Chen, S.1    Jiang, B.2    Da, W.3    Gong, M.4    Guan, M.5
  • 28
    • 34548737638 scopus 로고    scopus 로고
    • A prospective study of cyclosporine A treatment of patients with low-risk myelodysplastic syndrome: presence of CD55(-)CD59(-) blood cells predicts platelet response
    • Ishikawa T., Tohyama K., Nakao S., et al. A prospective study of cyclosporine A treatment of patients with low-risk myelodysplastic syndrome: presence of CD55(-)CD59(-) blood cells predicts platelet response. Int J Hematol 2007, 86:150-157.
    • (2007) Int J Hematol , vol.86 , pp. 150-157
    • Ishikawa, T.1    Tohyama, K.2    Nakao, S.3
  • 29
    • 0034084440 scopus 로고    scopus 로고
    • Prolonged response to cyclosporin-A in hypoplastic refractory anemia and correlation with in vitro studies
    • Catalano L., Selleri C., Califano C., et al. Prolonged response to cyclosporin-A in hypoplastic refractory anemia and correlation with in vitro studies. Haematologica 2000, 85:133-138.
    • (2000) Haematologica , vol.85 , pp. 133-138
    • Catalano, L.1    Selleri, C.2    Califano, C.3
  • 30
    • 0033965450 scopus 로고    scopus 로고
    • Good response to cyclosporine therapy in patients with myelodysplastic syndromes having the HLA-DRB1*1501 allele
    • Okamoto T., Okada M., Yamada S., et al. Good response to cyclosporine therapy in patients with myelodysplastic syndromes having the HLA-DRB1*1501 allele. Leukemia 2000, 14:344-346.
    • (2000) Leukemia , vol.14 , pp. 344-346
    • Okamoto, T.1    Okada, M.2    Yamada, S.3
  • 32
    • 0345701967 scopus 로고    scopus 로고
    • A pilot study of antithymocyte globulin (ATG) in the treatment of patients with 'low-risk' myelodysplasia
    • Killick S.B., Mufti G., Cavenagh J.D., et al. A pilot study of antithymocyte globulin (ATG) in the treatment of patients with 'low-risk' myelodysplasia. Br J Haematol 2003, 120:679-684.
    • (2003) Br J Haematol , vol.120 , pp. 679-684
    • Killick, S.B.1    Mufti, G.2    Cavenagh, J.D.3
  • 33
    • 0037443455 scopus 로고    scopus 로고
    • Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome
    • Steensma D.P., Dispenzieri A., Moore S.B., Schroeder G., Tefferi A. Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome. Blood 2003, 101:2156-2158.
    • (2003) Blood , vol.101 , pp. 2156-2158
    • Steensma, D.P.1    Dispenzieri, A.2    Moore, S.B.3    Schroeder, G.4    Tefferi, A.5
  • 34
    • 1542608520 scopus 로고    scopus 로고
    • A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes
    • Stadler M., Germing U., Kliche K.O., et al. A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes. Leukemia 2004, 18:460-465.
    • (2004) Leukemia , vol.18 , pp. 460-465
    • Stadler, M.1    Germing, U.2    Kliche, K.O.3
  • 35
    • 79951996237 scopus 로고    scopus 로고
    • Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care-SAKK 33/99
    • Passweg J.R., Giagounidis A.A., Simcock M., et al. Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care-SAKK 33/99. J Clin Oncol 2011, 29:303-309.
    • (2011) J Clin Oncol , vol.29 , pp. 303-309
    • Passweg, J.R.1    Giagounidis, A.A.2    Simcock, M.3
  • 36
    • 33744492061 scopus 로고    scopus 로고
    • Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes
    • Broliden P.A., Dahl I.M., Hast R., et al. Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes. Haematologica 2006, 91:667-670.
    • (2006) Haematologica , vol.91 , pp. 667-670
    • Broliden, P.A.1    Dahl, I.M.2    Hast, R.3
  • 37
    • 78650354414 scopus 로고    scopus 로고
    • Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions
    • Sloand E.M., Olnes M.J., Shenoy A., et al. Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions. J Clin Oncol 2010, 28:5166-5173.
    • (2010) J Clin Oncol , vol.28 , pp. 5166-5173
    • Sloand, E.M.1    Olnes, M.J.2    Shenoy, A.3
  • 38
    • 20144363954 scopus 로고    scopus 로고
    • Antileukemic activity of rapamycin in acute myeloid leukemia
    • Recher C., Beyne-Rauzy O., Demur C., et al. Antileukemic activity of rapamycin in acute myeloid leukemia. Blood 2005, 105:2527-2534.
    • (2005) Blood , vol.105 , pp. 2527-2534
    • Recher, C.1    Beyne-Rauzy, O.2    Demur, C.3
  • 39
    • 0036174289 scopus 로고    scopus 로고
    • Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor
    • Guba M., von Breitenbuch P., Steinbauer M., et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002, 8:128-135.
    • (2002) Nat Med , vol.8 , pp. 128-135
    • Guba, M.1    von Breitenbuch, P.2    Steinbauer, M.3
  • 40
    • 20044396552 scopus 로고    scopus 로고
    • Activity of sirolimus in patients with myelodysplastic syndrome-results of a pilot study
    • Platzbecker U., Haase M., Herbst R., et al. Activity of sirolimus in patients with myelodysplastic syndrome-results of a pilot study. Br J Haematol 2005, 128:625-630.
    • (2005) Br J Haematol , vol.128 , pp. 625-630
    • Platzbecker, U.1    Haase, M.2    Herbst, R.3
  • 41
    • 33745968917 scopus 로고    scopus 로고
    • Clinical applications and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia
    • Cheson B.D., Greenberg P.L., Bennett J.M., et al. Clinical applications and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006, 108:419-425.
    • (2006) Blood , vol.108 , pp. 419-425
    • Cheson, B.D.1    Greenberg, P.L.2    Bennett, J.M.3
  • 42
    • 0031464758 scopus 로고    scopus 로고
    • Overexpression of tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma by bone marrow cells from patients with myelodysplastic syndromes
    • Kitagawa M., Saito I., Kuwata T., et al. Overexpression of tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma by bone marrow cells from patients with myelodysplastic syndromes. Leukemia 1997, 11:2049-2054.
    • (1997) Leukemia , vol.11 , pp. 2049-2054
    • Kitagawa, M.1    Saito, I.2    Kuwata, T.3
  • 43
    • 0031656518 scopus 로고    scopus 로고
    • A role for tumor necrosis factor-a, Fas and Fas-Ligand in marrow failure associated with myelodysplastic syndrome
    • Gersuk G.M., Beckham C., Loken M.R., et al. A role for tumor necrosis factor-a, Fas and Fas-Ligand in marrow failure associated with myelodysplastic syndrome. Br J Haematol 1998, 103:176-188.
    • (1998) Br J Haematol , vol.103 , pp. 176-188
    • Gersuk, G.M.1    Beckham, C.2    Loken, M.R.3
  • 44
    • 0037411227 scopus 로고    scopus 로고
    • Expression of TNF receptors and related signaling molecules in the bone marrow from patients with myelodysplastic syndromes
    • Sawanobori M., Yamaguchi S., Hasegawa M., et al. Expression of TNF receptors and related signaling molecules in the bone marrow from patients with myelodysplastic syndromes. Leuk Res 2003, 27:583-591.
    • (2003) Leuk Res , vol.27 , pp. 583-591
    • Sawanobori, M.1    Yamaguchi, S.2    Hasegawa, M.3
  • 45
    • 18044404398 scopus 로고    scopus 로고
    • Immunosuppressive therapy for patients with refractory anemia
    • Asano Y., Maeda M., Uchida N., et al. Immunosuppressive therapy for patients with refractory anemia. Ann Hematol 2001, 80:634-638.
    • (2001) Ann Hematol , vol.80 , pp. 634-638
    • Asano, Y.1    Maeda, M.2    Uchida, N.3
  • 46
    • 23944523111 scopus 로고    scopus 로고
    • Cyclosporin A in myelodysplastic syndrome: a preliminary report
    • Dixit A., Chatterjee T., Mishra P., et al. Cyclosporin A in myelodysplastic syndrome: a preliminary report. Ann Hematol 2005, 84:565-568.
    • (2005) Ann Hematol , vol.84 , pp. 565-568
    • Dixit, A.1    Chatterjee, T.2    Mishra, P.3
  • 47
    • 0036840455 scopus 로고    scopus 로고
    • Effects of cyclosporine on hematopoietic and immune functions in patients with hypoplastic myelodysplasia: in vitro and in vivo studies
    • Selleri C., Maciejewski J.P., Catalano L., et al. Effects of cyclosporine on hematopoietic and immune functions in patients with hypoplastic myelodysplasia: in vitro and in vivo studies. Cancer 2002, 95:1911-1922.
    • (2002) Cancer , vol.95 , pp. 1911-1922
    • Selleri, C.1    Maciejewski, J.P.2    Catalano, L.3
  • 48
    • 0242643661 scopus 로고    scopus 로고
    • Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes
    • Yazji S., Giles F.J., Tsimberidou A.M., et al. Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes. Leukemia 2003, 17:2101-2106.
    • (2003) Leukemia , vol.17 , pp. 2101-2106
    • Yazji, S.1    Giles, F.J.2    Tsimberidou, A.M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.